Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for Mortality of Patients With Burn Injuries

15 augusti 2026 uppdaterad av: Ain Shams University

Measurement of Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for 30-day Mortality of Patients With Burn Injuries

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.

After consent, patients' characteristics (age, sex, weight), clinical parameters (total burn surface area, Abbreviated Burn Severity Index), and comorbidities will be recorded.

  1. Emergency Department (ED) management (Arrival and Initial Stabilization)

    • Primary survey (ATLS principles): Immediate stabilization of Airway, Breathing, Circulation, Disability, Exposure (ABCDE).

    • Urinary catheter insertion to monitor urine output for proper resuscitation.
    • TBSA will be estimated using the Rule of Nines
    • All patients will be treated during the first 24 hours after burn injury guided by the Parkland Formula.
  2. In-Hospital Resuscitation (0-72 h)

    • Hemodynamic monitoring: ECG, pulse oximetry, respiratory rate, temperature, non-invasive blood pressure, arterial line if unstable, and central venous pressure.

    • Transition to Day 2 (24-48 h post-burn): Continue Lactated Ringer's and consider colloid therapy (5% albumin or plasma) after 24 h to maintain oncotic pressure and reduce crystalloid load.

    • Fluid adjustments according to urine output, mean arterial pressure with target MAP (≥65 mmHg), lactate clearance, and base deficit.

    Laboratory and calculation:

    On admission to ED, an arterial blood gas (ABG) sample will be collected to calculate base deficit (BD) and lactate level.

    Simultaneously, venous blood will be drawn for C-reactive protein (CRP) and serum albumin, CBC, serum urea, creatinine, AST, ALT, and electrolytes (Na+, K+, Mg+) estimation.

    Red Cell Distribution Width/Albumin will be calculated as:

    ((RDW (Standard Deviation of Red Blood Cell Volume / Mean Corpuscular Volume) × 100%.) / albumin (g/L)) from admission labs.

    Serial: Lactate/Base Deficit at 6 hr, 12 hr, 24 hr as a monitor for proper resuscitation Calculation of Severity Scores

    • R-Baux score: Age (years) + %TBSA + (17 × inhalation injury [yes=1, no=0])

    • Abbreviated Burn Severity Index (ABSI): The ABSI includes five parameters: sex, age category, %TBSA, presence of full-thickness burns, and inhalation injury. Each parameter is assigned weighted points, and the total ABSI score is associated with graded survival probabilities.

    Both scores will be calculated on admission and compared with admission (RDW/albumin) ratio to assess relative and incremental predictive value for 30-day mortality.

    Supportive care:

    • Early enteral nutrition, proper multimodal analgesia (paracetamol 1gm/8hr, nalbuphine 0.1mg/kg if VAS score>4), IV proton pump inhibitor to guard against curling ulcer, prophylactic anticoagulation to guard against DVT.
    • Vasopressors (norepinephrine) only after adequate fluid resuscitation guided by UOP, lactate and BD if MAP below 65 mmHg.

      3 - Post-Resuscitation and Definitive Management Protocol (After 72 h) Hemodynamic stabilization (post-resuscitation phase) Transition from resuscitation fluids to maintenance fluids. Avoid "fluid creep" (excess positive balance leading to pulmonary edema, abdominal compartment). → cautious use of diuretics to mobilize edema.

    Maintain: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/h. Ongoing ventilatory support if required; lung-protective strategy for ARDS. Weaning as early as possible.

    Infection prevention and sepsis monitoring

    • Daily wound assessment for signs of infection, weekly or targeted wound/blood cultures and antibiotics only if infection is suspected/proven (not prophylactic).

    Wound care and surgical management

    • Regular dressing, use of negative-pressure wound therapy when indicated.

    • Early excision and grafting after 72 hr. Pain and sedation control
    • Multimodal analgesia, pre-procedure analgesia for dressing/grafting and long-term psychological and pain management.

    Rehabilitation and functional recovery • Early physiotherapy, occupational therapy for daily living skills and psychosocial support for patient and family.

    Criteria for transfer to ward • Hemodynamically stable, off vasopressors.

    • Stable oxygenation without advanced ventilatory support.

    • Tolerating enteral feeding.

    • Wounds coverage completed or adequately covered with new TBSA% below 20%.

    • Patients will be followed for 30 days at Ain Shams University burn unit. Measured outcomes

    Primary outcome:

    To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30-day hospital mortality in burn patients.

    Secondary outcomes:

    To determine the correlation between Red Cell Distribution Width/Albumin with:

    • ICU length of stay
    • Hospital length of stay
    • Requirements of inotropes or vasopressors
    • Duration of mechanical ventilation
    • To compare Red Cell Distribution Width/albumin ratio with R-Baux score as a predictor of mortality in burn patients.

Studietyp

Observationell

Inskrivning (Beräknad)

30

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Sara H Saleh, MD
  • Telefonnummer: +201001584305

Studieorter

    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypten, 11111
        • Rekrytering
        • Ain Shams University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Sannolikhetsprov

Studera befolkning

Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.

After consent, Patients' characteristics (age, sex, weight), clinical parameters (Total burn surface area, Abbreviated burn severity index), and comorbidities will be recorded.

Beskrivning

Inclusion Criteria:

  • Age > 18 years.
  • Both sexes.
  • Patients with burn injuries (%TBSA >20%).
  • Availability of complete laboratory data (RDW, albumin) on admission.
  • Admission to ICU within 24 hours of burn injury.

Exclusion Criteria:

  • Age <18 years.
  • Patients with chronic hematologic disease.
  • Pre-existing liver disease.
  • Nephrotic syndrome.
  • patients on chemotherapy.
  • Patients with incomplete or missing lab records.
  • Pregnant females.
  • Patient or guardian refusal.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
• Patients with burn injuries (%TBSA >20%)
each patient will be followed for 30 days for mortality prediction

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
mortality in burn patients
Tidsram: 30 days
To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.
30 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
ICU length of stay
Tidsram: 30 days
To determine the correlation between Red Cell Distribution Width/Albumin with o ICU length of stay
30 days
Requirements of inotropes or vasopressors
Tidsram: 30 days

To determine the correlation between Red Cell Distribution Width/Albumin with

o Requirements of inotropes or vasopressors

30 days
Duration of mechanical ventilation
Tidsram: 30 days

To determine the correlation between Red Cell Distribution Width/Albumin with

o Duration of mechanical ventilation

30 days
To compare RDW/albumin ratio with Revised Baux score as a predictor of mortality in burn patient.
Tidsram: 30 days
Revised Baux score = (percent body surface burned) + (patient's age) + 17 (if inhalational injury is present) A higher Revised Baux score generally indicates a higher risk of mortality, with scores over 140 unsurvivable .
30 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Adel M Fahmy Shenouda, MD, Department of Anesthesia, Intensive care and pain management, Faculty of Medicine, Ain Shams University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 augusti 2026

Primärt slutförande (Beräknad)

1 februari 2027

Avslutad studie (Beräknad)

1 april 2027

Studieregistreringsdatum

Först inskickad

8 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

8 augusti 2026

Första postat (Faktisk)

12 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • FMASU MD361/2025

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data underlying the study results will be made available upon reasonable request from qualified researchers

Tidsram för IPD-delning

Within 6:12 months

Kriterier för IPD Sharing Access

Access will be granted to researchers who submit a methodologically sound proposal to the principal investigator. Requests should be directed to g19-29502090100101@med.asu.edu.eg

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera